Preliminary 2027 CLFS medians point to lower reimbursement for many laboratory tests. Diagnostics leaders should assess exposure by code, review Medicare-linked contracts, and plan how to protect portfolio economics and margins through 2029.
CMS’s proposed laboratory rate changes will lead to decreases in reimbursement across a number of codes. If these changes are implemented, the commercial implications could extend well beyond Medicare and will continue to have an impact beyond 2027.
On September 21st, CMS published preliminary private-payer (including managed care vendors) medians for the 2027 Clinical Laboratory Fee Schedule (CLFS). The agency reports an average potential change of approximately 16% below 2026 rates for tests with a calculable median. However, this is not uniform across every test, understanding the nuances is critical to setting future commercial strategy.
For diagnostics businesses, the impact could extend from Medicare payments into payer/provider contracts as well as decreasing margins over several years. The starting point should be a code-level commercial assessment, not a blanket percentage reduction in the budget.
What is changing on January 1, 2027?
The Protecting Access to Medicare Act of 2014 (PAMA) established a shift from historical Medicare laboratory prices to rates based on the volume-weighted median of private-payer payments. That methodology first took effect in 2018. Initial reductions were capped at 10% annually through 2020; subsequent legislation delayed reporting and prevented PAMA phase-in reductions from 2021 through 2026.
Applicable laboratories, through their reporting entities, reported payment rates and volumes to CMS using data from January 1 through June 30, 2025. In other words, laboratories reported the payments they received from private payers; the payers did not submit the laboratory reports themselves.
CMS describes the pricing update as an effort to align Medicare payments with private-market rates and estimates approximately $1 billion in annual savings. The agency expects to finalize rates in November, with implementation scheduled for January 1st, 2027.
Diagnostics businesses must review the data carefully and prepare commercial teams for the scheduled implementation. Final rates and any subsequent legislative changes still need to be reflected before budgets and contracts are finalized.
The headline average hides very different portfolio exposures
CMS calculated medians for 1,528 codes (of the 1947 codes in the CLFS). Of these, 1,171 have lower median rates than their 2026 rates, 169 are unchanged, and 186 have higher rates. The critical distinction is that CMS is conducting a repricing exercise benchmarked against private payer rates, not a blanket reduction. Additionally, CMS did not take into account the % of volume of patient lives that commercial payers cover by test as well as how comprehensive their analysis was in terms of percent of commercial claims analyzed.
The differences between test categories also vary widely. CMS reports the following potential weighted rate changes, before applying the annual reduction protection.
Figure 1. Potential weighted rate changes versus CY 2026 across all 24 test categories. Uses the raw-median column in Summary_Stats_Wgt_Meds, weighted by reported private-payer test volume. These are preliminary comparisons before the cap, not final 2027 payable reductions or a forecast for an individual laboratory.
The preliminary data shows a comparatively small impact for PLA tests (proprietary laboratory analyses). As the name suggests, these tests are differentiated from existing market offerings and have unique codes. Given their differentiated nature and ability to tie test specific evidence with the PLA code, commercial payers are more likely to agree to stronger rates, relatively close to Medicare levels.
Figure 2. Code-level distribution of uncapped changes from 2026 CLFS rates to preliminary 2027 raw weighted medians, not first-year payable changes. Includes 1,526 comparable codes; no volume weighting. Excludes 419 codes without numeric medians and two without a positive 2026 baseline. Regular bins span 10 percentage points; the final bin includes all increases of 100% or more.
A 15% annual cap is not a 15% total cap
For existing CLFS codes subject to the phase-in, the maximum reduction is 15% of the preceding year's payment in each of 2027, 2028, and 2029. The cap limits the annual step toward the applicable median; it does not limit the cumulative reduction to 15%.
Commercial pricing can also create a feedback effect. Where contracts reset as a percentage of the prevailing Medicare rate, lower Medicare payments can reduce the private-payer median used in a later PAMA cycle. Fixed-rate contracts and repricing lags can dampen or delay that effect.
Figure 3 shows how PAMA will lower reimbursement until it meets the commercial payer median. Since commercial contracting is often negotiated as a percent of Medicare, the target median could continue to drop if CMS chooses to update their benchmarks (as displayed in orange).
Figure 3. Illustrative Medicare phase-in and commercial-pricing feedback. Medicare declines 15% annually from $100; the commercial median declines an assumed 5% annually from $60 to $51.44. The dotted $60 line is the fixed current-cycle PAMA target. The commercial path is illustrative, not a forecast.
What should diagnostics executive teams be asking?
The commercial response starts with five questions for diagnostics leaders. Each connects reimbursement changes to pricing, contracting, and portfolio decisions. We must ask the crucial question. “What does this all of this mean for your business?” The practical response should connect reimbursement analysis to commercial decisions. Five questions provide a useful starting point.
1. Which codes account for the largest Medicare exposure?
Map the current CLFS rate, preliminary median, estimated phased payment, and actual Medicare volume for each relevant code. Keep codes without medians in a separate scenario rather than assigning them a zero change. Prioritize the codes (tests/SKUs) that have the greatest impact on organizational revenue or profit, not simply those with the biggest reimbursement rate cuts.
2. Which contracts transmit CLFS changes beyond Medicare?
Diagnostic manufacturers ultimately sit one step removed from reimbursement decisions. Updates to CLFS will impact how labs are reimbursed for Medicare and could also flow through agreements tied to Medicare fee schedules (usually at some percent of Medicare).
Manufacturers need to assess their contracts with labs and distributors to see how renewal dates, opt-out clauses, cost-share, exclusivity agreements, and other factors will play a role in the spillover impact.
3. What is the EBITDA exposure through 2029?
Build a bridge from direct Medicare changes to contractual spillover and then to earnings. Make explicit assumptions about volume, payer mix, variable costs, and the timing of countermeasures. Do not assume that a lower reimbursement rate is offset by a proportionate reduction in cost.
The output should be a multi-year view of earnings before interest, taxes, depreciation, and amortization (EBITDA), with named actions behind the mitigation. Potential actions include payer renegotiation, provider-client pricing, procurement, productivity improvements, and changes to test routing or the test menu.
For manufacturers, the effects may emerge over time as contracts with labs and distributors may be locked in for several years. Other stakeholders within the value chain may also be willing to absorb some level of impact, but businesses must test that assumption rather than rely on it.
4. Does our portfolio and pipeline still support the intended economics?
Assess whether growth plans rely on tests whose reimbursement assumptions have changed. Revisit the evidence supporting clinical differentiation, the intended payer mix, and the price required to sustain the offering.
Apply the same discipline to acquisition cases and integration plans. Test whether expected margins and synergies still hold under the code-level payment trajectory, rather than carrying forward an unchanged reimbursement assumption.
5. What do current contracts imply for customer expectations?
Ultimately, manufacturers sit a level upstream from reimbursement decisions. Contracts may insulate from the rollover effects of lower reimbursement rates, till such contracts are renewed.
Note that customers may ask to open and renegotiate contracts prior to renewal given the shifting market conditions. While doing so may be voluntary; it is important to understand the competitive environment and risks of either course of action.
From exposure assessment to commercial action
Prepared diagnostics organizations will be able to explain their exposure at assay level and connect it to specific decisions: which contracts to renegotiate, which evidence to strengthen, where to improve delivery economics, and which investments to revisit. The objective is not a uniform response to a headline cut, but a tailored response to the economics of each portfolio.
The immediate technical step is to review the preliminary data. CMS has published medians with and without its duplicate and outlier exclusions. Assess whether those differences materially affect important codes, and support any comments with a clear, reproducible analysis.
In parallel, businesses must develop the commercial response. Where feasible, evaluate alternatives to automatic linkage with the prevailing CLFS and prepare the clinical and economic rationale for negotiations. Sequence operational and portfolio actions by their expected impact, feasibility, and implementation time.
At Simon-Kucher, our experts support diagnostics businesses in assessing reimbursement exposure and developing portfolio, pricing, and contracting strategies. We help translate these assessments into strategic and commercial playbooks, and support evidence-based responses to CMS proposals and preliminary payment determinations.
Leadership teams must understand how Medicare payment changes scheduled for implementation in January 2027 could affect their businesses and decide which actions must be prioritized.
How we can help
As your organization looks to address the changing tides of PAMA and CLFS, Simon-Kucher maintains a leading team of healthcare and reimbursement experts who are happy to speak with you and provide guidance. Key topics include comment/response support, impact estimation, risk mitigation, commercial strategy alignment, and reimbursement strategies.
To discuss what the proposed changes could mean for your business, contact our experts Chris Barr, Lynn Replogle and Jessica Cortez.
